Arvinas Inc - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating peer group for Arvinas Inc are displayed below. If you work at Arvinas Inc and you wish to use your Sustainability rating, please contact us. This report of Arvinas Inc employs data points from across the web and also from available filings by Arvinas Inc.
Arvinas Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 5.7, social score of 6.0 and governance score of 4.0.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 808 | Tilray Inc | 5.6 | High |
| 808 | Y-mAbs Therapeutics Inc | 5.6 | High |
| 835 | Arvinas Inc | 5.5 | High |
| 835 | Animalcare Group PLC | 5.5 | High |
| 835 | Bafna Pharmaceuticals Ltd | 5.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Arvinas Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Arvinas Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Arvinas Inc report the average age of the workforce?
Sign up for free to unlockDoes Arvinas Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Arvinas Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Arvinas Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Arvinas Inc offer flexible work?
Sign up for free to unlockDoes Arvinas Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Arvinas Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Arvinas Inc conduct supply chain audits?
Sign up for free to unlockDoes Arvinas Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Arvinas Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Arvinas Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Arvinas Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Arvinas Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Arvinas Inc disclose water use targets?
Sign up for free to unlockDoes Arvinas Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Arvinas Inc have a product recall in the last two years?
Sign up for free to unlockDoes Arvinas Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Arvinas Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Arvinas Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Arvinas Inc disclose parental leave metrics?
Sign up for free to unlockDoes Arvinas Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Arvinas Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Arvinas Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Arvinas Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Arvinas Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Arvinas Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Arvinas Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Arvinas Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Arvinas Inc disclose its waste policy?
Sign up for free to unlockDoes Arvinas Inc report according to TCFD requirements?
Sign up for free to unlockDoes Arvinas Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Arvinas Inc disclose energy use targets?
Sign up for free to unlockDoes Arvinas Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Arvinas Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Arvinas Inc
These potential risks are based on the size, segment and geographies of the company.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.